|
Species
|
Human
|
|
Accession
|
P00747
|
|
GeneID
|
5340
|
|
Source
|
Escherichia coli.
|
|
Molecular Weight
|
重组人血管抑素蛋白Approximately 29.7 KDa, a single non-glycosylated polypeptide chain containing 259 amino acids.
|
|
Quantity
|
10µg/50µg/1000µg
|
|
AA Sequence
|
VYLSECKTGN GKNYRGTMSK TKNGITCQKW SSTSPHRPRF SPATHPSEGL EENYCRNPDN DPQGPWCYTT DPEKRYDYCD ILECEEECMH CSGENYDGKI SKTMSGLECQ AWDSQSPHAH GYIPSKFPNK NLKKNYCRNP DRELRPWCFT TDPNKRWELC DIPRCTTPPP SSGPTYQCLK GTGENYRGNV AVTVSGHTCQ HWSAQTPHTH NRTPENFPCK NLDENYCRNP DGKRAPWCHT TNSQVRWEYC KIPSCDSSP
|
|
Purity
|
重组人血管抑素蛋白> 95 % by SDS-PAGE and HPLC analyses.
|
|
Biological Activity
|
Fully biologically active when compared to standard. The specific activity determined by an assay on anti-proliferation and anti-migration using endothelial cells in vitro and anti-angiogenesis in vivo is 5.5 × 105 IU/mg.
|
|
Physical Appearance
|
Sterile Filtered White lyophilized (freeze-dried) powder.
|
|
Formulation
|
Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM NaAc, pH 5.5, 4 % mannitol.
|
|
Endotoxin
|
Less than 1 EU/μg of rHuAngiostatin as determined by LAL method.
|
|
Reconstitution
|
重组人血管抑素蛋白We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
|
|
Storage
|
This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles.
|
|
重组人血管抑素蛋白
|
|
|
Reference
|
1. Takahashi S, Shinya T, Sugiyama A. 2010. J Pharmacol Sci, 112: 432-7.
2. Frank KFandMuller-Ehmsen J. 2009. Heart, 95: 269-70.
3. Perri SR, Annabi B, Galipeau J. 2007. FASEB J, 21: 3928-36.
4. Kim KS, Kim HS, Park JS, et al. 2004. Cancer Gene Ther, 11: 441-9.
5. Wahl ML, Owen CS, Grant DS. 2002. Endothelium, 9: 205-16.
|
|
Background
|
Angiostatin, is a ~30 kDa fragment of plasminogen that is encoded by the PLG gene in humans. It is produced, for example, by autoproteolytic cleavage of plasminogen, involving extracellular disulfide bond reduction by phosphoglycerate kinase. Furthermore, angiostatin can be cleaved from plasminogen by different metalloproteinases (MMPs), elastase, prostate-specific antigen (PSA), 13 kDa serine protease, or 24 kDa endopeptidase. Angiostatin is known to bind many proteins, especially to angiomotin and endothelial cell surface ATP synthase but also integrins, annexin II, C-met receptor, NG2 proteoglycan, tissue-type plasminogen activator, chondroitin sulfate proteoglycans, and CD26. It seems to involve inhibition of endothelial cell migration, proliferation and induction of apoptosis, but its mechanism of action is still unclear. Angiostatin is currently undergoing clinical trials for its use in anticancer therapy. Recombinant angiostatin is expressed in E. coli.
|
